Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|10|E130-E140

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.10, 2015-10, pp. : E130-E140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Half‐dose sorafenib for HCC

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 3, 2015-03 ,pp. : 279-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1036-1047

John Wiley & Sons Inc

Access to resources Recommend Favorite

Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan

By  

Oncology, Vol. 78, Iss. 1, 2010-07 ,pp. : 154-166

Karger

Access to resources Recommend Favorite

Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 5, 2015-05 ,pp. : 1581-1589

John Wiley & Sons Inc

Access to resources Recommend Favorite

MicroRNA‐425‐3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1077-1086

John Wiley & Sons Inc

Access to resources Recommend Favorite